Claims Court Role In Pipeline Patents Urged; Amgen Wants Bolar Limited
Patent restoration requests for drugs in the pipeline at the time of enactment of the Waxman/Hatch Act could be referred to the Federal Court of Claims for resolution, U.S. Federal Court of Appeals Judge Randall Rader suggested June 10 at a panel sponsored by the International Intellectual Property and Congressional Economic Leadership Institutes.
You may also be interested in...
Proposed legislation to reform the drug patent term restoration process could undercut FDA's "scientific judgements" by transferring undue authority to the Patent and Trademark Office, Sen. Leahy (D-Vt.) said during the Senate Judiciary committee's Aug. 4 hearing, "Pipeline Drugs: Proposed Remedies for Relief in S 1172."
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011